clenbuterol and Prosthesis Durability

clenbuterol has been researched along with Prosthesis Durability in 1 studies

Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.

Research

Studies (1)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Absolute Change in Left Ventricular Ejection Fraction From Explant to 18 Months Following Device Explant

(NCT00585546)
Timeframe: 18 months after explantation

Mean Change in Left Ventricular Ejection Fraction From Device Implant to Completion of Clenbuterol Therapy

(NCT00585546)
Timeframe: up to 16 months, variable based on length of time receiveing clenbuterol

Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 6 Months

Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited. (NCT00585546)
Timeframe: 6 months following LVAD implantation

Number of Subjects Who Received Maximum Target Dose of Clenbuterol

(NCT00585546)
Timeframe: Up to 16 months after LVAD implantation (12 months after beginning clenbuterol)

Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation

(NCT00585546)
Timeframe: One year after LVAD explant or until transplant or death (if not explanted)

The Number of Evaluable Subjects Meeting Explant Criteria and Subsequently Explanted

(NCT00585546)
Timeframe: Maximum 12 months after LVAD implantation

Time to Device Explant for Subjects Meeting Explant Criteria Defined in the Protocol

Time from LVAD placement to explant for the single participant who achieved explant (NCT00585546)
Timeframe: Time to explant (but not to be followed for more than 16 months)

Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Clenbuterol

(NCT00585546)
Timeframe: baseline to week 8 post clenbuterol

Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Implant

(NCT00585546)
Timeframe: Up to 8 weeks after LVAD implantation

Mean Change in EuroQoL Visual Analog Scale (EQ5D-VAS) From Baseline to 6 Months and 1 Year Following Device Implant

Scale 0 - 100 where 0 is worst possible health state and 100 is perfect health. (NCT00585546)
Timeframe: 1 year following LVAD implantation

Biologic Efficacy: Inflammation Marker - C-Reactive Protein

The primary endpoint was a reduction in inflammatory markers, specifically C-reactive protein (CRP). (NCT02547766)
Timeframe: 6 months post treatment

Biologic Efficacy: Inflammation Marker - Neutrophil Count

Secondary endpoints included the measure of additional inflammatory markers, including neutrophil count. (NCT02547766)
Timeframe: 6 months post treatment

Biologic Efficacy: Inflammation Marker - TNFalpha

Secondary endpoints included the measure of additional inflammatory markers, including TNFalpha. (NCT02547766)
Timeframe: 6 months post treatment

Clinical Efficacy: Ejection Fraction

Clinical efficacy was a secondary endpoint that was measured using ejection fraction (EF) (NCT02547766)
Timeframe: 6 months post treatment

Trials

1 trial available for clenbuterol and Prosthesis Durability